ArticleMolecular medicine reports2021
Ginsenoside Re exhibits neuroprotective effects by inhibiting neuroinflammation via CAMK/MAPK/NF‑κB signaling in microglia.
Article in Molecular medicine reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 47 citations in OpenAlex.
- Article
- Working Memory Impairment Induced by Chemotherapy-A Narrative Review.Brain sciences · 2026Review
- Total Saponins of Panax Notoginseng Leaves Modulate the "Microglial-NLRP3/Caspase-1" Axis associated with Gut Microbial/SCFAs Alterations: Correlative Insights into Cognitive Improvement in Senescence.Molecular neurobiology · 2026Article
- Targeting glial cells: Unveiling the neuroprotective mechanisms of Ginseng in the brain microenvironment.Acta pharmaceutica Sinica. B · 2026Review
- Ginsenoside Re mitigates AβJournal of ginseng research · 2026Article
- Natural Products in the Treatment of Neuroinflammation at Microglia: Recent Trend and Features.Cells · 2025Review
- Ginsenoside-Re-rich ethanol extract of Panax ginseng berry enhances healthspan extension via mitostasis and NAD metabolism.Journal of ginseng research · 2025Article
- Research progress on plant-derived natural compounds regulating the MAPK signaling pathway for the prevention and therapy of Alzheimer's disease.Frontiers in pharmacology · 2025Review
- Ginsenoside Rg1 in Parkinson's disease: from basic research to clinical applications.Frontiers in pharmacology · 2025Review
- Research advances on CaMKs-mediated neurodevelopmental injury.Archives of toxicology · 2024Review
- Activation of NF-κB/MAPK signaling and induction of apoptosis by salicylate synthase NbtS inmSystems · 2024Article
- Recent trends in ginseng research.Journal of natural medicines · 2024Review
- Brain plasticity and ginseng.Journal of ginseng research · 2024Review
- Network pharmacology-guided and TCM theory-supportedHeliyon · 2023Article
- Ginsenoside Re Mitigates Photooxidative Stress-Mediated Photoreceptor Degeneration and Retinal Inflammation.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2023Article
- American Ginseng for the Treatment of Alzheimer's Disease: A Review.Molecules (Basel, Switzerland) · 2023Review
- Ginsenosides fromInternational journal of molecular sciences · 2023Review
- Use of invertebrates to model chemically induced parkinsonism-symptoms.Biochemical Society transactions · 2023Review
- Ginsenoside Rg1 Delays Chronological Aging in a Yeast Model via CDC19- and SDH2-Mediated Cellular Metabolism.Antioxidants (Basel, Switzerland) · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ginsenoside Re (G‑Re) is a panaxatriol saponin and one of the pharmacologically active natural constituents of ginseng (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.